EUR 4.6
(-3.97%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 3.59 Million EUR | 3.03% |
2022 | 3.48 Million EUR | 253.94% |
2021 | -2.26 Million EUR | 59.74% |
2020 | -5.62 Million EUR | -42344.0% |
2019 | -13.24 Thousand EUR | 0.0% |
2018 | - EUR | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 FY | 3.59 Million EUR | 3.03% |
2023 Q2 | - EUR | -100.0% |
2022 Q4 | 3.48 Million EUR | 1226.76% |
2022 Q2 | -309.32 Thousand EUR | 86.34% |
2022 FY | 3.48 Million EUR | 253.94% |
2021 Q4 | -2.26 Million EUR | 4.76% |
2021 FY | -2.26 Million EUR | 59.74% |
2021 Q2 | -2.37 Million EUR | 57.73% |
2020 Q2 | -359.73 Thousand EUR | 0.0% |
2020 Q4 | -5.62 Million EUR | -1463.21% |
2020 FY | -5.62 Million EUR | -42344.0% |
2019 FY | -13.24 Thousand EUR | 0.0% |
2018 FY | - EUR | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
MPH Health Care AG | 8.5 Million EUR | 57.765% |
Apontis Pharma AG | -20.8 Million EUR | 117.265% |
Dermapharm Holding SE | 921.66 Million EUR | 99.61% |
Evotec SE | 115.28 Million EUR | 96.885% |
MERCK Kommanditgesellschaft auf Aktien | 7.95 Billion EUR | 99.955% |
PharmaSGP Holding SE | 33.21 Million EUR | 89.187% |